Double-bind cross-over tiral of flurbiprofen and phenylbutazone in ankylosing spondylitis.
A double-blind cross-over study in 35 patients with ankylosing spondylitis was carried out comparing flurbiprofen (150 mg daily)-a new non-steroidal anti-inflammatory agent-with phenylbutazone (300 mg daily) over a four-week period. Flurbiprofen was well tolerated and shown to have therapeutic efficacy approaching that of phenylbutazone. The results suggest that flurbiprofen may prove a valuable alternative in the treatment of ankylosing spondylitis, and longterm efficacy and tolerance studies are clearly indicated.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D005461:Fluorine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D011422:Propionates / Q000009:adverse effects / Q000627:therapeutic use*; D013131:Spine / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000503:physiopathology; D014717:Vertigo / Q000139:chemically induced
D000893:Anti-Inflammatory Agents; D001713:Biphenyl Compounds; D011422:Propionates; D005461:Fluorine; D010653:Phenylbutazone